The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > COLUMN
COLUMN
- The Evolving US Managed Care Environment and Implications of US Market Attractiveness for Japanese Manufacturers
September 5, 2022
- Fairness, Not Diversity
August 26, 2022
- Healthcare Collaboration between Governments and Biopharma: Key Success Factors for Life Science Manufacturers and Future Implications
August 5, 2022
- The Winning Combination: Drive, Passion, and Commitment
July 22, 2022
- Please Come Back to the Office!
June 24, 2022
- Customer Engagement in the COVID-Endemic New Normal
June 17, 2022
- Tapping into One’s Ikigai by Working from Home
May 27, 2022
- The Road to Success Is Paved with the Stepping-Stones of Disappointment
April 22, 2022
- Five Ways to Get Your New Hire on the Same Page
March 31, 2022
- 4 Things You Can Do to Overcome Zoom Overload
November 26, 2021
- What Does a Great Boss Look Like?
October 29, 2021
- What Is the Price of a Work-Life Balance?
September 24, 2021
- Obituary: P. Reed Maurer
September 14, 2021
- Digital and Cultural Transformation in Japanese Pharmaceuticals
August 13, 2021
- How Manufacturers Can Optimize Wholesaler Relationships and Leverage Wholesalers to Support Business Strategy
July 13, 2021
- Does Your Company Want to Increase Its Diversity?
July 5, 2021
- 5 Lessons in 5 Years from Rocking the Bag
June 17, 2021
- Pricing Reform in Japan - How Manufacturers Can Ensure Fair Compensation for Value and Innovation
May 28, 2021
- Set the Stage for an Exceptional Customer Experience
May 21, 2021
- Pricing Reform in Japan: How Must Life Science Companies Evolve?
April 23, 2021
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…